Trial Radar
Sign in

NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

Drug Intensive Monitoring Study of Olaparib in Clinical Practice Among Chinese Patients
Drug Intensive Monitoring Study of Olaparib in Clinical Practice Among Chinese Patients

NCT04560452

CompletedN/A

Sponsor: AstraZeneca

Conditions: Ovarian Cancer, Prostate Cancer

Countries: China

This is a multi-centre, prospective, non-interventional study. The study will enrol about 860 Chinese cancer patients from around 56 sites. For OC cohort, the subjects who had received olaparib for at least one dose before study enrolment in real world practices will be enrolled ( n=800) . For PC cohort, according to the doctor's decision, patients who have prescribed and agreed to start taking at least one dose of Olaparib will be enrolled ( n=60). Patient's treating physician is in charge of prescribing (including dose-adjusting or interruption) or discontinuation of olaparib.

Eligibility overview

Sex: ALL

Healthy volunteers: No

Study type: OBSERVATIONAL

Eligibility criteria
Inclusion Criteria

* Provision of signed and dated written informed consent by the patient or legally acceptable representative prior to any study-specific procedures
* Patients diagnosed as olaparib approved tumor types in China
* Eligible for olaparib treatment per the judgement of the treating physician in clinical practice
* For OC cohort: at least take one tablet of olaparib before enrolment
* For PC cohort: according to the doctor's decision, have prescribed and agreed to start taking at least one dose of Olaparib

Exclusion Criteria

• In other ongoing studies, which prohibit any participation in this non-interventional study judged by investigator.
Locations (37)
  • Anhui, China
  • Beijing, China
  • Changsha, China
  • Chengdu, China
  • Chongqing, China
  • Dongguan, China
  • Foshan, China
  • Fujian, China
  • Guangdong, China
  • Guangzhou, China
  • Guangzho, China
  • Guizhou, China
  • Hangzhou, China
  • He'nan, China
  • Hebei, China
  • Heilongjiang, China
  • Henan, China
  • Huizhou, China
  • Jiangsu, China
  • Jiangxi, China
  • Jilin City, China
  • Jinghou, China
  • Liaoning, China
  • Luzhou, China
  • Nanjing, China
  • Nantong, China
  • Ningbo, China
  • Shandong, China
  • Shanghai, China
  • Shenyang, China
  • + 7 more on CT.gov